Mounjaro Lawsuit [2026 Update]

Mounjaro and Other GLP-1 Drugs Linked to Serious Side Effects

Mounjaro and other GLP-1-related medications have been linked to severe gastrointestinal complications in current lawsuits and regulatory safety discussions.

Reported complications include gastroparesis, delayed gastric emptying, severe nausea, persistent vomiting, bowel obstruction, severe constipation, abdominal pain, dehydration, and other digestive-system injuries that may require hospitalization or long-term treatment.

Mounjaro’s prescribing information states that the medication delays gastric emptying and has been associated with gastrointestinal adverse reactions, sometimes severe.

The label also states that Mounjaro is not recommended for patients with severe gastroparesis.

Plaintiffs in current lawsuits allege that Eli Lilly and Company failed to adequately warn patients and healthcare providers about the severity, persistence, and potential long-term consequences of these gastrointestinal risks.

The federal GLP-1 gastrointestinal injury litigation is coordinated in MDL No. 3094 in the U.S. District Court for the Eastern District of Pennsylvania.

According to the court, the MDL includes claims involving Ozempic, Wegovy, and Rybelsus, manufactured by Novo Nordisk, along with Mounjaro and Trulicity, manufactured by Eli Lilly and Company.

Plaintiffs allege these medications can cause gastroparesis and other gastrointestinal injuries, while Eli Lilly and Novo Nordisk deny the allegations.

What Is Mounjaro and Is It Different Than Other GLP-1 Drugs?

Mounjaro is the brand name for tirzepatide, an injectable prescription medication manufactured by Eli Lilly and Company for adults with type 2 diabetes.

It belongs to a broader group of injectable medications commonly discussed alongside Ozempic and Mounjaro in current GLP-1 litigation and weight loss drug safety discussions.

Like other GLP-1-related medications, Mounjaro affects appetite, blood sugar regulation, insulin response, and gastric emptying, which may help some patients lose weight.

Mounjaro differs from some other weight loss medications because tirzepatide acts on both GLP-1 and GIP hormone pathways rather than GLP-1 activity alone.

The same digestive-slowing effect that may help patients lose weight is also central to current allegations involving gastroparesis, stomach paralysis, and other severe gastrointestinal complications.

Mounjaro is commonly associated with:

• Type 2 diabetes treatment
• Blood sugar regulation
• Appetite suppression
• Delayed gastric emptying
• Weight management and metabolic treatment
• GLP-1 and GIP receptor activity
• Gastrointestinal side effects linked to slowed digestion

What Serious Risks Are Alleged in Mounjaro Lawsuits?

Mounjaro lawsuits allege that Eli Lilly failed to adequately warn patients and doctors about severe gastrointestinal side effects linked to the drug.

These claims focus on whether Mounjaro can cause or contribute to stomach paralysis, delayed gastric emptying, bowel obstruction, and other severe gastrointestinal events.

The Mounjaro label includes warnings for severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, and diabetic retinopathy complications in certain patients.

It also lists common adverse reactions such as nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.

Mounjaro lawsuits commonly involve allegations of:

• Stomach paralysis: Also called gastroparesis, this condition can prevent the stomach from emptying normally.
• Severe vomiting: Persistent vomiting can lead to dehydration, emergency care, and hospitalization.
• Bowel obstruction: Some claims involve ileus, intestinal obstruction, or pseudo-obstruction.
• Severe constipation: Serious constipation may lead to fecal impaction or urgent medical treatment.
• Dehydration and kidney injury: Severe vomiting or diarrhea may cause volume depletion and kidney complications.
• Long-term digestive problems: Some users allege ongoing nausea, abdominal pain, food intolerance, and inability to eat normally.

Health Problems Linked to Mounjaro, Ozempic, Wegovy, and Other Similar Drugs

Mounjaro, Ozempic, Wegovy, and other GLP-1 medications have been linked to serious stomach issues in current lawsuits.

These injectable drugs are used for type 2 diabetes, chronic weight management, or related conditions, but plaintiffs allege that drug manufacturers failed to properly warn patients about severe gastrointestinal problems connected to delayed gastric emptying.

Mounjaro’s prescribing information states that the drug delays gastric emptying and has been associated with gastrointestinal adverse reactions, sometimes severe.

The label also states that Mounjaro is not recommended in patients with severe gastroparesis, and it includes warnings for acute kidney injury due to volume depletion in patients with reactions that may cause dehydration.

Health problems alleged in lawsuits involving Mounjaro and similar drugs include:

• Stomach paralysis or gastroparesis
• Delayed gastric emptying
• Severe nausea and vomiting
• Excessive vomiting
• Stomach pains and abdominal pain
• Bowel obstruction or intestinal obstruction
• Severe constipation or fecal impaction
• Dehydration
• Malnutrition
• Acute kidney injury related to dehydration
• Emergency room visits or hospitalization

Plaintiffs claim these stomach problems can become serious when the digestive system slows to the point that food does not move normally through the stomach and intestines.

The federal GLP-1 gastrointestinal injury cases are coordinated in federal court through MDL No. 3094, which includes claims involving Mounjaro and Trulicity, manufactured by Eli Lilly and Company, and Ozempic, Wegovy, and Rybelsus, manufactured by Novo Nordisk.

What Is Severe Gastroparesis?

Severe gastroparesis is a digestive disorder that slows or prevents the stomach from emptying food normally.

It is sometimes called stomach paralysis because the stomach muscles do not move food through the digestive system as they should.

Mounjaro lawsuits allege that some users may experience stomach paralysis after taking the drug because Mounjaro can delay gastric emptying.

While this effect may help regulate appetite, blood sugar, and body weight, plaintiffs allege it can also lead to severe stomach issues in some patients.

Symptoms of severe gastroparesis may include:

• Persistent nausea
• Severe vomiting
• Stomach pains
• Bloating
• Feeling full after eating small amounts
• Food staying in the stomach too long
• Loss of appetite
• Unintended weight loss
• Dehydration
• Malnutrition
• Blood sugar instability
• Repeated emergency room visits

Severe gastroparesis may lead to major medical costs when patients need diagnostic testing, IV fluids, hospitalization, prescription medication, feeding support, or long-term gastrointestinal care.

A Mounjaro legal team may review medical records, prescription history, symptom timing, and treatment records to determine whether the facts support a potential claim.

Mounjaro and Vision Loss

Some safety concerns involving Mounjaro and similar GLP-1 drugs involve vision changes or vision loss.

Mounjaro’s label warns about diabetic retinopathy complications in patients with a history of diabetic retinopathy and states that those patients should be monitored for progression.

Separate from diabetic retinopathy, recent research has examined whether semaglutide or tirzepatide may be associated with an increased risk of optic nerve disorders, including non-arteritic anterior ischemic optic neuropathy, or NAION.

A 2025 JAMA Network Open study found that semaglutide or tirzepatide was associated with increased risk of NAION and other optic nerve disorders, but the overall risk was low and prior findings have been inconsistent.

Vision loss should be discussed separately from the main gastrointestinal injury claims.

The primary Mounjaro lawsuit focus remains stomach paralysis, delayed gastric emptying, bowel obstruction, and other serious gastrointestinal issues.

Patients who experience sudden vision changes after using Mounjaro should seek medical care promptly and preserve ophthalmology records, prescription records, and communications with healthcare providers.

Do You Qualify for the Mounjaro Lawsuit?

You may qualify for a Mounjaro lawsuit if you developed serious gastrointestinal issues after taking Mounjaro, including gastroparesis, stomach paralysis, intestinal blockages, severe vomiting, or other severe digestive side effects.

Mounjaro is a diabetes drug manufactured by Eli Lilly and Company, and plaintiffs claim the company failed to adequately warn patients and healthcare providers about the risk of severe gastrointestinal adverse events.

A potential claim may depend on several factors, including:

• Whether you were taking Mounjaro before symptoms began
• Whether a medical professional diagnosed you with gastroparesis, stomach paralysis, ileus, bowel obstruction, or intestinal obstruction
• Whether you experienced severe vomiting, excessive nausea, dehydration, or life-threatening complications
• Whether you required emergency room care, hospitalization, diagnostic testing, or long-term treatment
• Whether your medical records support a timeline connecting Mounjaro use to the injury
• Whether you suffered medical expenses, lost wages, or other damages

People who were previously taking Ozempic, Wegovy, Trulicity, or similar drugs may still have legal options, but the medication history must be reviewed carefully.

These medications work by affecting appetite, blood sugar, and gastric emptying, which is central to the stomach paralysis allegations in the GLP-1 litigation.

Mounjaro’s prescribing information states that use has been associated with gastrointestinal adverse reactions, sometimes severe, and that Mounjaro is not recommended in patients with severe gastroparesis.

Gathering Evidence for Mounjaro Lawsuits

Evidence is important in Mounjaro lawsuits because each claim must connect the medication, timing of symptoms, diagnosis, treatment, and damages.

A legal team can help gather records, but patients can begin preserving documents before the legal process starts.

Useful evidence in Mounjaro lawsuits may include:

• Medical records showing diagnosis, symptoms, treatment, and follow-up care
• Prescription records showing when you started taking Mounjaro, dosage changes, and refill history
• Diagnostic testing, such as gastric emptying studies, endoscopy, imaging, or hospital records
• Emergency room records or hospitalization records for severe gastrointestinal issues
• Records from a medical professional, including GI specialist notes
• Medication history, including Ozempic, Wegovy, Trulicity, or similar drugs
• Symptom timelines showing when stomach problems, severe vomiting, or bowel symptoms began
• Medical bills and insurance documents showing medical expenses
• Employment records showing missed work or lost wages
• Communications with doctors, pharmacies, Eli Lilly, or insurers

Plaintiffs claim this evidence can show whether Eli Lilly’s Mounjaro caused or contributed to serious side effects and whether the companies failed to adequately warn users about the risk of severe digestive injuries.

Damages in Mounjaro Lawsuits

Damages in Mounjaro lawsuits depend on the facts of each case.

Plaintiffs who filed lawsuits may seek compensation for the physical, financial, and personal losses they experienced after developing serious gastrointestinal issues.

Possible damages may include:

• Medical expenses for emergency care, hospitalization, testing, medication, and follow-up treatment
• Future medical costs for ongoing gastrointestinal care
• Lost wages from missed work
• Loss of earning capacity if symptoms affect long-term employment
• Pain and suffering from severe vomiting, stomach pain, bowel obstruction, or gastroparesis
• Loss of enjoyment of life if the injury affects eating, daily activities, travel, or work
• Out-of-pocket costs related to treatment, nutrition changes, transportation, or caregiving

There is no guaranteed Mounjaro lawsuit settlement.

Any potential recovery would depend on diagnosis, injury severity, medical history, proof of drug use, treatment records, and damages.

No universal Mounjaro settlements have been announced for all claimants.

Is There a Mounjaro Class Action Lawsuit?

There is not currently a traditional class action lawsuit for Mounjaro stomach paralysis injuries.

Many federal GLP-1 gastrointestinal injury claims are being handled through multidistrict litigation, or MDL No. 3094, in the U.S. District Court for the Eastern District of Pennsylvania.

The MDL includes claims involving Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.

The official federal court page states that Mounjaro and Trulicity are manufactured by Eli Lilly and Company, while Ozempic, Wegovy, and Rybelsus are manufactured by Novo Nordisk.

The court also states that plaintiffs allege GLP-1 medications can cause gastroparesis and other gastrointestinal injuries, while Eli Lilly and Novo Nordisk deny the allegations.

An MDL is different from a class action lawsuit.

In an MDL:

• Each plaintiff keeps an individual lawsuit
• Cases are coordinated before one federal judge
• Shared evidence and pretrial issues are handled together
• Any potential settlement or payout depends on the facts of each person’s case

Mounjaro claims are part of broader GLP-1 mass torts, where patients claim pharmaceutical companies failed to adequately warn about the risk of serious side effects.

What Drug Manufacturer Is Named in the Mounjaro Lawsuits?

The main manufacturer named in Mounjaro lawsuits is Eli Lilly and Company.

Plaintiffs are suing Eli Lilly over allegations that the company failed to adequately warn patients and healthcare providers about the risk of severe gastrointestinal side effects linked to Eli Lilly’s Mounjaro.

Mounjaro’s label also includes a boxed warning for thyroid C-cell tumors based on animal studies.

The prescribing information states that Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, or MTC, or Multiple Endocrine Neoplasia syndrome type 2.

This warning should be discussed separately from the stomach paralysis claims because the current Mounjaro lawsuits primarily focus on gastrointestinal injuries.

TorHoerman Law: Lawyers for the Mounjaro Lawsuit

TorHoerman Law is reviewing Mounjaro lawsuit claims involving people who experienced severe gastrointestinal issues after taking Mounjaro.

Our legal team can review your medical records, prescription history, diagnosis, treatment timeline, medical expenses, lost wages, and other damages to determine whether your facts may support a claim.

If you or a loved one experienced severe side effects after taking Mounjaro, contact TorHoerman Law for an initial consultation.

You can also use the chatbot on this page to see if you qualify today.

Our lawyers can explain the legal process, answer your questions, and help determine whether you may be eligible to seek compensation through a Mounjaro lawsuit.